Tassos Gianakakos - MyoKardia
San Francisco-based firm MyoKardia has appointed Tassos Gianakakos as its new CEO, replacing founding CEO Charles Homcy who remains on the Board.
He joins the firm from MAP Pharmaceuticals (acquired by Allergan in March 2013) where he was most recently senior vice president and chief business officer, and has previously led the formation of Codexis.
“I am delighted to welcome Tassos to the MyoKardia team given his track record of growing and transforming research-stage organizations with meaningful drug platforms into clinical and commercial-stage companies,” said Homcy
“Tassos is a proven industry leader with deep scientific, financial, operational and business development experience, which will be invaluable to MyoKardia as the team continues to develop our platform targeting genetic heart disease and rapidly advance our lead cardiomyopathy program toward the clinic.”